Could fewer infusions tame thyroid eye disease?
NCT ID NCT07308964
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a shortened 4-infusion course of the drug Teprotumumab (Tepezza) against the standard 8-infusion course for people with active thyroid eye disease. Only patients who show a good early response will be eligible for the shorter regimen. The goal is to see if fewer infusions can be just as effective and safe, potentially saving time and reducing side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Teprotumumab (Tepezza)
- What this could lead to
- If successful, this could mean fewer infusions for patients who respond quickly, reducing treatment burden and side effects while maintaining effectiveness.
- What could go wrong
- This is a small Phase 4 study with only 40 participants, so results may not apply to all patients. The shorter course might not control the disease as well long-term, and risks like hearing problems or muscle spasms from teprotumumab remain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody calm thyroid eye disease?
- Could a cholesterol drug shrink eye muscle swelling in thyroid eye disease?
- Can a pill reverse eye bulging in thyroid eye disease?
- Can an experimental drug reduce eye bulging in thyroid eye disease?
- Can a new drug ease bulging eyes in thyroid disease?
- Could your Phone's camera help track thyroid eye disease?